Insulin Resistance and Testosterone in Women

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Insulin ResistancePostmenopause
Interventions
DRUG

metformin

Initiated on 500 mg daily and titrated up to 1000 mg twice a day during the first four weeks, remaining at that dose until 12 weeks

DRUG

leuprolide injection

3.75 mg injection every 4 weeks (e.g. at baseline, 4, and 8 weeks)

DRUG

placebo pill

matching pill twice a day for 12 weeks

DRUG

placebo injection

matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)

Trial Locations (1)

19104

University of Pennsylvania Clinical and Translational Research Center, Philadelphia

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

The John A. Hartford Foundation

OTHER

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

University of Pennsylvania Diabetes and Endocrinology Research Center (DERC)

OTHER

collaborator

TAP Pharmaceutical Products Inc.

INDUSTRY

lead

University of Pennsylvania

OTHER

NCT00123110 - Insulin Resistance and Testosterone in Women | Biotech Hunter | Biotech Hunter